EGFR and non-small cell lung carcinoma: Our present study provides evidence that targeting the Golgi apparatus by M-COPA might be a promising therapeutic approach to overcome the vicious cycle of TKI resistance in EGFR-mutated NSCLC cells via a completely different mode of action, i.e., downregulating the cell surface expression of EGFR with a TKI-resistant mutation.